Cisplatin, the backbone of NAC for urothelial carcinoma, induces muscle wasting through several molecular mechanisms, including disruption of the ubiquitin–proteasome system, alterations in intracellular calcium homeostasis, activation of the PI3K/AKT pathway, and mitochondrial lesions [56]. Here, AKT1 is linked to urothelial carcinoma.